MichaelWFriedMDFAASLD

Gastroenterology • Chapel Hill, NC

Hepatology & Liver Transplantation

Professor of Medicine, University of North Carolina School of Medicine

Join to view full profile

Dr. Fried is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fried's full profile

Already have an account?

Office
University of North Carolina
101 Manning Drive
Chapel Hill, NC 27514
Phone+1 919-843-6386

Summary

Michael W. Fried, MD, FAASLD

is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. Dr. Fried served as President of the American Association for the Study of Liver Diseases (AASLD) in 2019. He completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.

From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for over 20 years as principal investigator on several NIH cooperative clinical trials and he currently serves as the co-chair of the Hepatitis B Research Network (NIDDK). Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network studying HCV therapies used in usual clinical practice and co-PI of PRIORITIZE, a pragmatic clinical trial of HCV therapeutics.

Dr. Fried is the primary author or co-author on over 200 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. He was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.

Education & Training

Clinical Center at the National Institutes of HealthFellowship, Liver Diseases, 1990 - 1993
SUNY Upstate Medical UniversityFellowship, Gastroenterology, 1987 - 1989
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1984 - 1987
Tel Aviv University SacklerClass of 1984

Certifications & Licensure

NY State Medical License 1984 - Present
NC State Medical License 1998 - 2024
GA State Medical License 1993 - 1999
MD State Medical License 1989 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

President American Association for the Study of Liver Diseases (AASLD), 2019
President-Elect American Association for the Study of Liver Diseases (AASLD), 2018
America's Top Doctors Castle Connolly, 2012-2018
Fellow, FAASLD American Association for the Study of Liver Diseases (AASLD), 2015
Fellow (AGAF) American Gastroenterological Association, 2009
Elected Member The American Society for Clinical Investigation, 2004
Join now to see all

Clinical Trials

Hepatitis C in Clinically Discordant Hemophilic Siblings Start of enrollment: 1999 Sep 01
Completed
Phase I Trial of Silymarin for Chronic Liver Diseases Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment Start of enrollment: 2008 Apr 01
Completed
Phase 2
Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Start of enrollment: 2008 Apr 01
Completed
Phase 2
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C Start of enrollment: 2009 Nov 01
Completed
Phase 1
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B Start of enrollment: 2012 May 01
Terminated
Phase 3
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation Start of enrollment: 1999 Nov 01
Completed
Phase 1, Phase 2
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Completed
Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir. Start of enrollment: 2011 Dec 01
Withdrawn
Study of Oral Treatments for Hepatitis C Start of enrollment: 2016 Jun 01
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

15 citations
Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.
Florian Froehlich, D. Hartmann, C. Guezelhan, J.-J. Gonvers, Jan B.M.J. Jansen
Digestive Diseases and Sciences. 1996-12-01
132 citations
Gastric flow and mixing studied using computer simulation.
Anupam Pal, K. Indireshkumar, Werner Schwizer, Bertil Abrahamsson, Michael Fried
Proceedings. Biological Sciences. 2004-12-22
249 citations
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
A. M. Di Bisceglie, H. S. Conjeevaram, Michael W. Fried, Richard Sallie, Yoon Park
Annals of Internal Medicine. 1995-12-15

Journal Articles

A Comprehensive Assessment of Patient Reported Symptom Burden, Medical Comorbidities, and Functional Well Being in Patients Initiating Direct Acting Antiviral Therapy ...
Souvik Sarkar, Michael W. Fried, Richard K. Sterling, Paul W. Stewart, Nancy Reau, Joseph K. Lim, David R. Nelson, Marina Serper, PLoS One

Lectures

Hepatitis C Management: State of the Art 2013
Hepatitis C Management, New York, New York - 5/9/2013

Press Mentions

Target RWE Announces the Launch of Engage™ - an Innovative, Digital Patient-Centric Engagement PlatformAugust 21st, 2024
World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment MilestoneJune 4th, 2024
New Partnership Launches Carolina Hepatitis Academic Mentorship ProgramMarch 14th, 2017

Grant Support

Mentoring Junior Faculty: Viral Hepatitis Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2012
The North Carolina Hepatitis Beta Clinical Research NetworkNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
Division Of Digestive Diseases Serum And Tissue BankNational Center For Research Resources2008
A Phase I/II Randomized, Placebo Controlled Trial Of Silymarin For Hepatitis CNational Center For Complementary &Alternative Medicine2006–2008
Mentoring Junior Faculty: Hepatitis C Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
Pegasys PLUS Amantadine And Pegasys PLUS Amantadine PLUS RibavirinNational Center For Research Resources2006
Virahep-C: A Study Of Antiviral Resistance In AFR Amer/Caucasian-Hep CNational Center For Research Resources2005–2006
Interferon Resistance In African-AmericansNational Center For Research Resources2004–2005
Hepatitis C Antiviral Resistance In African AmericansNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2005
Virahep-C: A Study Of Antiviral Resistance In Afr. Amer./Caucasian-Hep CNational Center For Research Resources2004
Pilot--Alcohol And Hepatitis C Host Response And Disease ActivityNational Institute On Alcohol Abuse And Alcoholism2003–2004
Hepatitis C In Clinically Discordant Hemophilic SiblingsNational Heart, Lung, And Blood Institute1999–2002
Famciclovir For Chronic Hepatitis BNational Center For Research Resources1997
Chronic Hepatitis C Infection In Urban African AmericansNational Institute Of Allergy And Infectious Diseases1996